Undisclosed CNS Candidate
Major Depressive Disorder (MDD)
Key Facts
About Alto Neuroscience
Alto Neuroscience is disrupting the trial-and-error approach in psychiatry by developing personalized medicines based on deep neurobiological insights. Built on 15 years of field-leading research, the company's clinical-stage pipeline targets core brain processes to help patients get better faster. Alto's precision approach uses brain biology measurements to predict clinical success and match patients with optimal treatments, offering a novel paradigm for treating serious mental health conditions.
View full company profileAbout Alto Neuroscience
Alto Neuroscience is disrupting the trial-and-error approach in psychiatry by developing personalized medicines based on deep neurobiological insights. Built on 15 years of field-leading research, the company's clinical-stage pipeline targets core brain processes to help patients get better faster. Alto's precision approach uses brain biology measurements to predict clinical success and match patients with optimal treatments, offering a novel paradigm for treating serious mental health conditions.
View full company profileAbout Alto Neuroscience
Alto Neuroscience is disrupting the trial-and-error approach in psychiatry by developing personalized medicines based on deep neurobiological insights. Built on 15 years of field-leading research, the company's clinical-stage pipeline targets core brain processes to help patients get better faster. Alto's precision approach uses brain biology measurements to predict clinical success and match patients with optimal treatments, offering a novel paradigm for treating serious mental health conditions.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| XEN1101 | Xenon Pharmaceuticals | Phase 3 |
| BHV-5000 (NMDA antagonist) | Biohaven | Phase 1 |
| Navacaprant (NMRA-140) | Neumora Therapeutics | Phase 3 |
| MW-101 | MindWalk Holdings | Phase 2 |
| NPH-101 | Neuphoria Therapeutics | Phase 2 |
| Itruvone (PH10) | Vistagen Therapeutics | Phase 2 |